NextPoint Therapeutics
Austin, US · Delaware corporation · 31 employees on LinkedIn · 10 known investors
Find your way into NextPoint Therapeutics
1,419 people in our graph share verified history with the NextPoint Therapeutics team — schools, employers, funds. One of them is your warm intro.
Anthony Philippakisunlockedknows Tatiana Novobrantseva · together at Harvard Medical School (overlapped)
knows the team · via Dana-Farber Cancer Institute
×3knows the team · via University of California, Berkeley
×2knows the team · via Harvard University
knows the team · via FairJourney Biologics
knows the team · via Moderna
NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor. Its pipeline of first-in-class immuno-oncology assets is aimed at cancer patients with B7-H7 upregulation, including those who do not respond to existing PD-1/L1 inhibitor therapies.
Founders & leadership
GF
Gordon FreemanScientific Founder
XZ
XingXing ZanginScientific FounderScientific founder of NextPoint Therapeutics, a precision cancer immunotherapy company; brings expertise in immune checkpoint biology and cancer immunotherapy from prior research that generated foundational intellectual property for multiple biotech startups.
IC
Ivan CheunginCEO & Member of Board of DirectorsIvan Cheung is Chief Executive Officer of NextPoint Therapeutics, a precision oncology company developing immunotherapies targeting the B7-H7/HHLA2 axis.
LG
Leena GandhiinChief Medical OfficerLeena Gandhi is a board-certified medical oncologist and physician-scientist with experience in translational research and clinical development, including leadership of phase I-III trials in lung cancer focused on immunotherapy and PD-L1 biomarkers. She has overseen immuno-oncology programs spanning early preclinical to late-stage development and established a clinical-translational research center at Dana-Farber Cancer Institute.
TN
Tatiana NovobrantsevainChief Scientific OfficerShe has led drug development programs across protein and nucleic acid therapeutics in immunology, inflammation, and immuno-oncology, and has experience scaling startups and securing funding.
AH
Axel HoosNamed on SEC filing
JL
Jeffrey LaceyNamed on SEC filing
Board
DB
RJ
R. Jacob Vogelsteinin𝕏Board directorCo-Founder and Managing Partner at Catalio Capital Management, LP
BS
PH
RD
Investors · 10
Catalio Capital Management, LPNew York
MPM BioImpactBoston · $1M – $15M
Sanofi VenturesCambridge · $5M
Catalio Capital ManagementreportedNew York
InvusreportedNew York
Leaps by Bayerreported · 2 sourcesLeverkusen
Sixty Degree CapitalreportedNorth York
Also in the syndicate · 3
Arkin Bio-CapitalDana-Farber Cancer Institute's Binney Street CapitalleadWTT Investment
Reported raises · per SEC filings
Form D private placements$156.2M disclosed across 3 rounds · 2022–2026
▶$33.7MraisedJul 2026 · 15 investors · BiotechnologyRule 506(b)
▶$33.7MraisedJul 2026 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Detlev BiniszkiewiczDirector
- Ivan CheungExecutive Officer, Director
- Axel HoosDirector
- R. Jacob VogelsteinDirector
- Brian ShusterDirector
- Paulina HillDirector
- Rakhshita DharDirector
- Jeffrey LaceyExecutive Officer
- Offering amount
- $48.7M
- Amount sold
- $33.7M
- Proceeds to insiders
- $2.5M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$42.5MraisedFeb 2024 · 15 investors · BiotechnologyRule 506(b)
▶$42.5MraisedFeb 2024 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew Roden)Director
- Axel HoosDirector
- Paulina HillDirector
- Ivan CheungExecutive Officer, Director
- Detlev BiniszkiewiczDirector
- Rakhshita DharDirector
- Paul ConradExecutive Officer
- R. Jacob VogelsteinDirector
- Offering amount
- $42.5M
- Amount sold
- $42.5M
- Proceeds to insiders
- $1.3M
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$80MraisedDec 2022 · 13 investors · BiotechnologyRule 506(b)
▶$80MraisedDec 2022 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paulina HillDirector
- Detlev BiniszkiewiczExecutive Officer, Director
- Paul ConradExecutive Officer
- Matthew RodenDirector
- Rakhshita DharDirector
- Ansbert GadickeDirector
- Offering amount
- $80M
- Amount sold
- $80M
- Proceeds to insiders
- $1.7M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Dewpoint Therapeutics24 shared keywordsDewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms. Its discovery engine combines biology, chemistry, proprietary datasets, and AI to pursue therapies for complex diseases, including previously undruggable targets.
Bioworld19 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with NextPoint Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Single-nucleus multimodal spatial transcriptomics reveals spatial colocalization of neoantigen-expressing tumor cells and cognate T cells | Nature Biotechnologynature.com · Jul 2026Frequently asked questions
- What does NextPoint Therapeutics do?
- NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor. Its pipeline of first-in-class immuno-oncology assets is aimed at cancer patients with B7-H7 upregulation, including those who do not respond to existing PD-1/L1 inhibitor therapies.
- Who founded NextPoint Therapeutics?
- NextPoint Therapeutics was founded by Gordon Freeman, XingXing Zang.
- Who are NextPoint Therapeutics's investors?
- NextPoint Therapeutics's investors include Catalio Capital Management, LP, MPM BioImpact, Sanofi Ventures, Catalio Capital Management, Invus, Leaps by Bayer, Sixty Degree Capital.
- How much funding has NextPoint Therapeutics raised?
- NextPoint Therapeutics has disclosed $156.2M raised across 3 rounds.
- Where is NextPoint Therapeutics headquartered?
- NextPoint Therapeutics is headquartered in Austin, US.